Novo Nordisk A/S buy Subdi
Summary
This prediction was cancelled by the user.Novo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by Subdi for this prediction
In the thread Novo Nordisk A/S diskutieren
Subdi stimmt der Buy-Einschätzung von t66wv33c zu
... setze mal ein Kauflimit von maximal 36,80 ...
Subdi stimmt am 24.05.2017 der Buy-Einschätzung von t66wv33c mit dem Kursziel 40,3€ zu.
Überschrift: immer noch billig!